Latest Boardroom Shifts News

QuickFee Limited posted a 25% increase in revenue to A$25.3 million for FY25, driven by strong growth in both Australia and the US, alongside a positive underlying EBTDA of A$2.4 million before a one-off credit loss provision.

Brambles Limited reported a solid FY25 with a 3% rise in sales revenue and a 10% increase in underlying profit, alongside progress on sustainability targets and a renewed board.

Vault Minerals reports a robust FY25 with A$1.43 billion revenue and a net profit of A$237 million, driven by full-year integration of Silver Lake Resources and operational advances. The company outlines a strategic two-stage expansion at King of the Hills and maintains a strong cash position post debt repayment.

Finbar Group Limited reported a robust 46% increase in revenue to $284.5 million for FY2025, despite a 12.5% decline in comprehensive profit. The company completed key residential projects and sharpened its focus on core property development in Western Australia.

Fisher & Paykel Healthcare has issued strong first half FY26 guidance, forecasting significant revenue and profit growth while navigating new US tariffs. Meanwhile, director Pip Greenwood announces her retirement after eight years on the board.

Kaili Resources has officially confirmed a change of control with Mr Jianzhong Yang now holding over 60% of shares, alongside a significant board reshuffle. The company remains focused on advancing its rare earth elements exploration in South Australia.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Alliance Aviation Services reported a robust 19% revenue increase to $769.7 million in FY25, driven by fleet expansion and strong operational performance. The company’s strategic investments and contract growth set a positive tone for FY26.

Prescient Therapeutics reported an 11.1% reduction in net loss for FY2025, progressing its lead candidate PTX-100 into Phase 2a trials with FDA Fast Track and Orphan Drug designations, supported by a recent $9.8 million capital raise.

Straker Ltd reported a 10% revenue decline in FY25 but achieved record gross margins and adjusted EBITDA, underscoring its strategic shift to AI-driven language services and expanding IBM partnership.

Genetic Technologies Limited has emerged from voluntary administration following a strategic asset sale and is now pursuing recapitalisation and acquisitions to restore its market position.

Genetic Technologies Limited reports a 36% increase in half-year losses amid voluntary administration, followed by a recapitalisation and sale of core assets. The company pivots towards new financial services acquisitions under fresh leadership.